After 40 years, new medicine for combating TB.

about

Multidrug-resistant tuberculosis treatment with linezolid-containing regimen.Bio-layer interferometry for measuring kinetics of protein-protein interactions and allosteric ligand effects.

P2860

Q33416970-CF582E54-BAA7-4855-B42E-F7C5579268DC Q42018301-32577033-157E-4A2C-8AC8-135A6FA6344F

P2860

After 40 years, new medicine for combating TB.

Item

http://www.wikidata.org/entity/Q42119482

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

After 40 years, new medicine for combating TB.

@en

After 40 years, new medicine for combating TB.

@nl

type

Item

label

After 40 years, new medicine for combating TB.

@en

After 40 years, new medicine for combating TB.

@nl

prefLabel

After 40 years, new medicine for combating TB.

@en

After 40 years, new medicine for combating TB.

@nl

P1476

After 40 years, new medicine for combating TB.

@en

P2860

Variations of Subunit of the Mycobacterium tuberculosis F1Fo ATP Synthase and a Novel Model for Mechanism of Action of the Tuberculosis Drug TMC207

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.

Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis

Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.

Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control.

Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells.

New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure.

P304

1-2

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.IJMYCO.2013.01.004

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mehdi Mirsaeidi

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257744593

http://www.w3.org/2001/XMLSchema#string

P698

25045621

http://www.w3.org/2001/XMLSchema#string

P932

4103685

http://www.w3.org/2001/XMLSchema#string

After 40 years, new medicine for combating TB.

about

P2860

P2860

After 40 years, new medicine for combating TB.

description

name

type

label

prefLabel

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932